Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets?
Authors
Brabant, Georg EAffiliation
Department of Endocrinology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, United Kingdom. georg.brabant@manchester.ac.ukIssue Date
2008-04
Metadata
Show full item recordCitation
Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? 2008, 93 (4):1167-9 J. Clin. Endocrinol. Metab.Journal
The Journal of Clinical Endocrinology and MetabolismDOI
10.1210/jc.2007-2228PubMed ID
18390811Type
ArticleLanguage
enISSN
0021-972Xae974a485f413a2113503eed53cd6c53
10.1210/jc.2007-2228
Scopus Count
Related articles
- Suppressive therapy in the management of metastatic thyroid carcinoma.
- Authors: Waldstein SS
- Issue date: 1980 Feb
- Insights from molecular pathways: potential pharmacologic targets of benign thyroid nodules.
- Authors: Eszlinger M, Jaeschke H, Paschke R
- Issue date: 2007 Oct
- Thyrocyte-specific Gq/G11 deficiency impairs thyroid function and prevents goiter development.
- Authors: Kero J, Ahmed K, Wettschureck N, Tunaru S, Wintermantel T, Greiner E, Schütz G, Offermanns S
- Issue date: 2007 Sep
- TSH induces metallothionein 1 in thyrocytes via Gq/11- and PKC-dependent signaling.
- Authors: Bäck CM, Stohr S, Schäfer EA, Biebermann H, Boekhoff I, Breit A, Gudermann T, Büch TR
- Issue date: 2013
- [Vasoconstrictive action of urotensin II].
- Authors: Ikeda K, Tojo K
- Issue date: 2004 Sep